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Abstract
Cisplatin-based chemotherapy is currently the standard treatment for locally advanced esophageal cancer. Cisplatin has
been shown to induce both apoptosis and necrosis in cancer cells, but the mechanism by which programmed necrosis is
induced remains unknown. In this study, we provide evidence that cisplatin induces necrotic cell death in apoptosis-
resistant esophageal cancer cells. This cell death is dependent on RIPK3 and on necrosome formation via autocrine
production of TNFa. More importantly, we demonstrate that RIPK3 is necessary for cisplatin-induced killing of esophageal
cancer cells because inhibition of RIPK1 activity by necrostatin or knockdown of RIPK3 significantly attenuates necrosis and
leads to cisplatin resistance. Moreover, microarray analysis confirmed an anti-apoptotic molecular expression pattern in
esophageal cancer cells in response to cisplatin. Taken together, our data indicate that RIPK3 and autocrine production of
TNFa contribute to cisplatin sensitivity by initiating necrosis when the apoptotic pathway is suppressed or absent in
esophageal cancer cells. These data provide new insight into the molecular mechanisms underlying cisplatin-induced
necrosis and suggest that RIPK3 is a potential marker for predicting cisplatin sensitivity in apoptosis-resistant and advanced
esophageal cancer.
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Introduction
Esophageal cancer is the sixth most common cancer worldwide,
and its highest incidence rates occur in Eastern Asia and Southern
and Eastern Africa [1,2]. The current standard of care for locally
advanced esophageal cancer includes chemotherapy and radio-
therapy without surgical treatment; chemotherapy consists of a
combination of cis-diamminedichloroplatinum II (cisplatin) and 5-
fluorouracil [3]. Apoptosis is well known to be the predominant
form of cell death mediating chemotherapy and radiotherapy
effectiveness [4,5]. However, the upregulation of anti-apoptotic
proteins and the downregulation of pro-apoptotic proteins often
allow tumor cells to circumvent apoptosis, and become resistant to
therapy during their evolution to malignancy [6]. Although
cisplatin has been demonstrated to involve DNA binding, forming
inter- and intra-stand covalent adducts, thus leading to apoptosis,
accumulating evidence has shown that cisplatin-induced DNA
adducts trigger both apoptosis and necrosis in cancer cells [7].
Apoptosis, as a process of programmed energy-driven, is
characterized by caspase activity, nuclear condensation, degrada-
tion of cellular proteins and the formation of apoptotic bodies,
with the maintenance of plasma membrane integrity. There are
two core pathways to induce apoptosis, the extrinsic-death
receptor pathway and the intrinsic-mitochondrial pathway. In
contrast, necrosis is characterized by plasma membrane rupture,
swollen organelles and release of cellular proteins into the
extracellular microenvironment. With the discovery of key
mediators of necrotic cell death such as RIPK1 and RIPK3,
accumulating data show that necrosis is also programmed cell
death. Recent evidence shows that caspase-8- and FADD-deficient
mice die at embryonic stage 10.5; which is rescued by co-deletion
of RIPK1 or RIPK3. This indicates that inhibition of the caspase-
8-dependent apoptotic pathway triggers RIPK3-dependent necro-
sis, leading to death during embryonic development [8,9]. Because
tumor cells evolve various strategies to evade apoptosis during
tumorigenesis, necrosis can be found in tumor tissues during
chemotherapy and radiotherapy [10,11]. Increasing evidence
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indicates that the process of cancer transformation is accompanied
by a shift from apoptosis to necrosis. Cancer cells can die by
different cell death modes including necrosis in response to
genotoxic drugs [12]. It has also been found that treatment of
tumor with cisplatin showed significantly released levels of HMGB
and caused necrosis, particularly in skin tumors [13]. The role of
necrotic cell death in chemotherapy has been increasingly
appreciated [14,15]. Nevertheless, the mechanisms of pro-
grammed necrosis induced by cisplatin remain largely unknown.
Recent evidence has demonstrated that TNFa triggers pro-
grammed necrosis following experimental inhibition of caspase
activation in a number of cell types [16]. RIPK3 has been
identified in a genome-wide siRNA screen as a critical necrosis
mediator which switches the cell fate from TNFa-induced
apoptosis to necrosis [17,18]. The execution of programmed
necrosis requires the functions of RIPK3 and RIPK1, and can be
blocked by the RIPK1 kinase inhibitor necrostatin and the RIPK3
inhibitor necrosulfonamide (NSA), especially when the apoptotic
pathways are suppressed [17,19,20,21]. RIPK1 and RIPK3 are
both important components of the necrosome, a death-signaling
complex that is required for necrosis in response to TNFa. Mixed
lineage kinase domain-like protein (MLKL) has recently been
identified as another essential member of the necrosome complex,
and a key downstream mediator of the RIPK3. This large multi-
protein complex has been characterized in the presence of caspase
inhibitors and a SMAC mimetic [22,23]. Phosphorylation of both
RIPK1 and RIPK3 stabilizes their association within the death-
signaling complex and results in the production of reactive oxygen
species (ROS) in certain cells by activating enzymes in metabolic
pathways [24,25]. The expression of RIPK3 has been detected in
a variety of cancer cell lines, which correlates with responsiveness
to necrosis induction [17]. However, whether RIPK3 is associated
with the cisplatin-induced necrosis is largely unknown.
In this study, we demonstrated that cisplatin selectively induces
necrosis in KYSE140, an esophageal squamous carcinoma
(ESCC) cell line deficient in SMAC, a pro-apoptotic protein.
Cisplatin triggers necrosome formation through autocrine pro-
duction of TNFa, leading to necrosis. Furthermore, inhibition of
RIPK activity by Nec-1 or knockdown of RIPK3 protein with
siRNA largely rescued cisplatin-induced necrosis. Moreover,
microarray analysis identified an anti-apoptotic molecular expres-
sion pattern in esophageal cancer cells in response to cisplatin.
Our data thus provide new insight into the molecular mechanisms
underlying cisplatin-induced necrosis in esophageal cancer che-
motherapy.
Materials and Methods
Cell culture and drug treatment
The esophageal cancer cell lines KYSE140 and KYSE410 were
obtained from Dr. Yutaka Shimada at Hyogo College of
Medicine[26]. EC0156 was established in our lab (19). All cell
lines were grown in RPMI supplemented with 10% FBS, 100 U/
ml penicillin, and 100 mg/ml streptomycin at 37uC in 5% CO2.
Cisplatin was purchased from the institutional pharmacy (QILU
Pharmaceutical Co., China). Cells were grown in 96-well plates to
20–30% confluence before treatment with anticancer drugs. After
cisplatin treatment for 24 or 48 h, cell death was analyzed using a
MTT assay.
Transfection and small interfering RNA (sh RNA)
knockdown
For RIPK3 and SMAC knockdown, KYSE140 cells grown in a
6-well plate were transfected with the pPuro-shRNA-RIPK3 and
pSilence-shRNA-Smac plasmids using Lipofectamine (Invitrogen,
USA) according to the manufacturer’s instruction [17] [27]. For
RIPK3 overexpression, KYSE410 cells were transfected with PCI-
RIPK3 vector using Lipofectamine (Invitrogen, USA) [17]. The
nonspecific small interfering RNA (siCtrl) oligonucleotides and
siRNA oligonucleotides targeting RIPK1 were obtained from Life
Technologies Co. (Ambion, USA). All siRNAs were transfected
into KYSE140 cells using the Lipofectamine Plus reagent
(Invitrogen) according to the manufacturer’s protocol.
The following abbreviations are used throughout the paper:
RIPK3-KD, a selected KYSE140 clone with reduced RIPK3
expression (14); PCI-RIPK3, a selected KYSE410 clone with
exogenous overexpression of RIPK3 from the PCI vector;
KYSE140-vec, KYSE140 cells transfected with the empty vector.
Measurement of TNFa and LDH in culture media by
ELISA
Cells grown in 10 cm dishes were treated at the indicated time
as described in figure legends. The culture media were collected,
and the concentrations of TNFa and LDH were determined with
a TNFa ELISA Kit (Invitrogen) and a lactate dehydrogenase
(LDH) ELISA Kit (Abcam) according to the manufacturers’
protocols.
Detection of cell death and viability
Cell death was detected by (i) nuclear morphological changes
examined under a microscope and (ii) the annexin V and
propidium iodide (PI) staining coupled with flow cytometry, as
described previously (19). Cell viability was assessed by the MTT
(AMRESCO, USA) assay using a Model 680 microplate reader
(Bio-Rad, CA) to quantify absorbency value according to the
manufacturer’s instruction. For the colony formation assay, cells
were seeded in 6-well plates at a density of 56105 cells per well,
treated with cisplatin for 12 h, and then cultured with fresh, drug-
free RPMI supplemented with 10% FBS. After 14 days, cells were
stained with 0.25% crystal violet (AMRESCO) for 20 min. All
experiments were repeated at least three times.
Immunoprecipitation and western blot analysis
Immunoprecipitation of RIPK1 and MLKL was performed
according to a previously described protocol [28]. Briefly, cells
cultured in 10-cm dishes were lysed for 30 min on ice in lysis
buffer containing 1% (w/v) Triton X-100, 0.15 M NaCl, 30 mM
Tris-HCl (pH 7.5) and protease inhibitors (Roche, Germany). The
lysates were sonicated and centrifuged at 10,000 g for 15 min at
4uC. One milligram of extracted protein in lysis buffer was
incubated overnight with 10 mg rabbit anti-RIPK1 or anti-MLKL
antibody followed by incubation with 20 ml Dynabeads Protein G
(Invitrogen, USA) for 2 h at 4uC and three washes with lysis
buffer. The beads were directly boiled in 1% SDS loading buffer
for 5 min. Subcellular fractions, including nuclear, membrane and
cytosolic fractions, were prepared using the proteoExtract sub-
cellular proteome extraction kit (Calbiochem, USA) according to
the manufacturer’s instructions.
Western blot analysis was performed as described previously
[27], using the following antibodies: anti-caspase-9, anti-caspase-3,
anti-Fos, anti-RIPK1, and anti-survivin antibodies from Cell
Signaling Technology (Beverly, MA); anti-RIPK3 and anti-SMAC
antibodies from Abcam (Cambridge, MA); anti-MLKL, anti-
cytochrome C and anti-Bcl-2 antibodies from Santa Cruz
Biotechnology.
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Microarray analysis
Total RNA was isolated from untreated and cisplatin-treated
KYSE140 cells using an RNeasy mini kit (Qiagen). The quality of
the total RNA was determined using a Nanodrop spectropho-
tometer (ND-2000; Thermo Fisher Scientific). RNA with an
A260/A280 absorbance ratio ranging from 1.8 to 2.0 was used for
cDNA synthesis. Gene expression profiles were analyzed on a
GeneChip Human Genome U133 Plus 2.0 array (Affymetrix,
Santa Clara, CA), which contains 54,000 probe sets representing
approximately 47,000 genes. Microarray hybridization was
performed at 45uC with rotation for 16 h using an Affymetrix
GeneChip Hybridization Oven 640. The stained GeneChip probe
array was scanned with the GeneChip Scanner 3000 7G
(Affymetrix) at 570 nm. The signal intensity of the gene expression
was analyzed to generate CEL files using the default setting of
Affymetrix GeneChip Command Console 3.2 (AGCC) Software.
The Affymetrix Microarray Suite 5.0 (MAS5) and the Robust
Multi-array Average (RMA) algorithm were used for the
expression summary and signal calculation of the GeneChip
Human Genome U133 2.0 data, respectively [29]. In a
comparison analysis, the two-classes unpaired method from the
Significance Analysis of Microarray software (SAM, version 3.02)
was used to compare the significantly differentially expressed genes
between the untreated and cisplatin-treated KYSE140 cells.
Differentially expressed genes were selected based on a .2.0-fold
change and a q value ,5%. The Entrez gene identifiers from the
genes were used to perform enrichment analysis using the
Database for Annotation, Visualization and Integrated Discovery
(DAVID) [30]. Geo series number is GSE56769.
Real-time PCR Analysis
Total RNA was isolated from the untreated and cisplatin-
treated KYSE140 cells using an RNeasy mini kit (Qiagen, USA).
The first-strand complementary synthesis reaction was performed
using the SuperScript III Reverse Transcriptase kit (Invitrogen,
USA). Primers were designed with Primer-Blast software (http://
www.ncbi.nlm.nih.gov/tools/primer-blast/). Amplification reac-
tions were conducted using the SsoFast EvaGreen Supermix with
a CFX 96 real time system (Chemoscience, USA). The complete
list of gene-specific real-time primers in this study is available in
Table S3. GAPDH served as an internal control to normalize the
loading of the template cDNA. Each experiment was repeated at
least twice, and the fold change in gene expression was assessed
using theDCt method [31].
Flow cytometric analysis
KYSE140 cells were treated with 10 mM cisplatin for 6 and
12 h, then incubated with 29,79-dichlorofluorescin diacetate
(H2DCF-DA) for 20 min after washing with PBS. ROS activation
was determined and analyzed using flow cytometry (EPICS
ELITE ESP, USA) to calculate the percentage of ROS-positive
cells according to the manufacturer’s protocol.
Transmission electron microscopy
KYSE140 cells cultured in chamber slides were treated with
10 mM cisplatin for 24 h, then fixed for 2 h with 2.5%
glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.4),
further fixed in osmium tetroxide solution for 1 h, and then
subjected to electron microscopy analysis with a Hitachi 7650
electron microscope.
Ethics statement
All experimental procedures for the use of animals were
previously reviewed and approved by the institutional animal
care and use committee (IACUC) at the Cancer Hospital of
Chinese Academy of Medical Science (Permit Number:
NCC2013A012). All surgery was performed under sodium
pentobarbital anesthesia, and all efforts were made to minimize
suffering.
In vivo xenograft assay
Animal experiments were carried out as previously described
[27]. Briefly, 56106 parental or PCI-RIPK3-D8 cells were
suspended in 100 ml PBS and injected subcutaneously into the
right flank of female nude mice (n=5). Tumor size was measured
every 2–3 days with digital calipers. Tumor volume was calculated
using the formula: 0.56a6b2, where a is the length of the tumor,
and b is the width.
Statistical analysis
Statistical analysis was performed using GraphPad Prism 5
software. Statistical comparisons were made using SPSS version
17.0. P-values ,0.05 were considered statistically significant.
Results
Cisplatin induces non-apoptotic cell death in SMAC-
deficient ESCC cells
Our previous work revealed that SMAC modulates chemosen-
sitivity and is essential for drug-induced apoptosis in esophageal
cancer [27]. In this study, we first asked whether the innate SMAC
deficiency facilitates cisplatin resistance in ESCC cells. As shown
in Figure 1A, western blot analysis of SMAC in ESCC cell lines
showed that 7 of the 8 lines express SMAC, except for KYSE140.
We chose KYSE140 as an innate SMAC-deficient cell model to
investigate cisplatin resistance. The sensitivities of EC0156 with
SMAC knockdown (SMAC-KD) and KYSE140 cells to cisplatin
were examined using annexin V-FITC and propidium iodide.
Intriguingly, we found that KYSE140 cells that are endogenously
SMAC-deficient were still sensitive to cisplatin-induced cell death
in comparison to the SMAC-KD cells (Figure 1B and 1D). To
investigate whether KYSE140 cells die via apoptosis, cells were
examined for apoptotic morphology. Substantial nuclear frag-
mentation and mitochondrial membrane potential were detected
in the positive control EC0156 cells, but not in the KYSE140 cells
after cisplatin treatment (Figure 1C and 2A), suggesting that
cisplatin induces non-apoptotic cell death in the KYSE140 cells.
These observations prompted us to further investigate the type
of cell death induced by cisplatin in KYSE140 cells using several
approaches. First, we analyzed the release of lactate dehydogenase
(LDH), a characteristic feature of necrotic cell death [32]. We
noticed that the release of LDH was apparently increased at 24
and 48 h after cisplatin treatment (Figure 2B). Next, we tested the
ROS production of the cisplatin-treated KYSE140 cells. ROS
production increased in response to cisplatin in KYSE140 cells
(Figure 2C). Furthermore, monitoring activation of the caspase
cascade by western blot analysis revealed little cleavage of caspase-
9 and caspase-3 after cisplatin treatment in KYSE140 cells,
whereas caspase cleavage was observed in the control EC0156
cells, further indicating a non-apoptotic form of cell death in
KYSE140 cells (Figure 2D). Further analysis using transmission
electron microscopy (TEM) showed a substantial percentage of
cisplatin-treated KYSE140 cells had discontinuous cytoplasm
membranes and swollen mitochondria, but lacked typical
apoptotic features such as plasma membrane blebbing (Figure
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Figure 1. Cisplatin-induced cell death in ESCC cells. (A) Total cellular protein extracts from each of the nine esophageal cancer cell lines were
subjected to western blot analysis for SMAC; SMAC-KD-D10 shows stable knockdown of SMAC. The levels of SMAC protein were quantified,
normalized to b-Actin, and are shown in the lower bar graph. (B) Apoptosis was observed in the KYSE140, EC0156, and SMAC-KD-D10 cells after
treatment with cisplatin for 24 h, using annexin V/propidium iodide staining and flow cytometry. (C) Nuclei were observed following nuclear staining
with DAPI. More apoptotic nuclei appeared in the EC0156 cells after exposure to cisplatin for 24 h, but few apoptotic nuclei were observed in the
treated KYSE140 cells. (D) Dose-dependence curve for the KYSE140, EC0156, and SMAC-KD-D10 cells after cisplatin treatment for 24 h and 48 h.
doi:10.1371/journal.pone.0100127.g001
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Figure 2. Cisplatin triggers programmed necrosis in KYSE140 cells. (A) Mitochondrial membrane potentials of KYSE140 and EC0156 cells
were determined using Mito Tracker Red CMXRos staining and analyzed by flow cytometry after cisplatin treatment for 24 h. (B) Cellular necrosis was
measured as LDH release after cisplatin treatment for 24 h and 48 h. (C) KYSE140 cells were treated as indicated for 12 h. The cells were stained with
H2DCF-DA for 20 min, and then ROS levels were measured using flow cytometry. All experiments were performed at least three times. (D) KYSE140
and EC0156 were treated with 10 mM cisplatin for 12 or 24 h. Caspase activation was assessed by western blotting. Arrowheads indicate caspase
cleavage fragments. (E) Total cellular protein extracts from each of the eight esophageal cancer cell lines were subjected to western blot analysis for
RIPK3. b-Actin as a loading control. (F) Transmission electron microscopy of the KYSE140 cells after cisplatin treatment. Membrane integrity was noted
in the control cells, and the collapse of the membrane and the swelling of the cellular organelles were noted in the cells treated with cisplatin.
doi:10.1371/journal.pone.0100127.g002
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2F-i and 2F-iii). Collectively, these data indicates that cisplatin
predominately induces non-apoptotic and caspase-independent
cell death in KYSE140 cells.
The molecular mechanisms of cisplatin-induced necrosis
in KYSE140 cells
RIPK3 has recently been identified as a critical modulator in
TNFa–induced necroptosis [17,33]. We examined the expression
levels of RIPK3 in several ESCC cell lines. As shown in Figure 2E,
western blot analysis showed that 6 of the 8 lines, including
KYSE140, expressed RIPK3, except for EC0156 and KYSE410
cells. We found that the transcription and protein expression of
RIPK3 gradually increased from 6–24 h after cisplatin treatment
compared to the untreated cells (Figure 3A&B). Autocrine
production of TNFa has recently been recognized as a critical
signal for the induction of necroptosis in response to zVAD and
Heme [34,35]. We tested whether autocrine production of TNFa
is involved in cisplatin-induced necrotic cell death in KYSE140
cells by analyzing TNFa mRNA levels using RT-PCR at the
indicated time points after cisplatin treatment. A higher level of
TNFa mRNA level was detected in cisplatin-treated KYSE140
cells than in control cells (Figure 3C). ELISA analysis detected a
low basal level of TNFa, approximately 3 pg/ml, in the media of
KYSE140 cells. The TNFa level was profoundly increased by over
15-fold upon cisplatin treatment for 6 or 12 h, suggesting that
cisplatin treatment enhances the transcription of TNFa and
autocrine production of TNFa in the media (Figure 3D). These
results are consistent with recent studies in which autocrine
production of TNFa was required for zVAD-induced cell death in
L929 cells [18,34].
It is known that functional necrosomes, formed by the binding
of RIPK3 to the RIPK1 kinase and the mixed lineage kinase
domain-like protein (MLKL), play key roles in TNFa-induced
necrosis [36,37]. Therefore, we sought to determine whether
cisplatin triggered the assembly of necrosome served as a cytosolic
signaling platform to initiate necrosis in KYSE140 cells. Anti-
RIPK1 and anti-MLKL antibodies were used to immunoprecip-
itate the endogenous RIPK3. The RIPK3/RIPK1/MLKL
complex was only weakly present in the untreated cells, but the
level of necrosomes markedly increased after cisplatin treatment
(Figure 3E). To verify the subcellular localization of the necrosome
complex, we also analyzed sub-cellular fractions of the cisplatin-
treated cells, including the cytosolic and the membrane/mito-
chondria protein fraction (Figure 3F). RIPK3 was enriched in the
cytosolic fraction and the membrane/mitochondria fraction after
12 h of cisplatin treatment. RIPK1 and MLKL were also slightly
enriched in the membrane fraction after cisplatin treatment.
Taken together, these data indicate that cisplatin triggers the
recruitment of the necrosome to mitochondrial membranes, which
involves autocrine production of TNFa.
RIPK3 and RIPK1 are required for cisplatin-induced
necrosis
Based on the finding that cisplatin triggers the formation of
necrosome, we asked whether cisplatin-induced cell death depends
on RIPK1 and RIPK3. RIPK3 was knocked down by shRNA
vectors in KYSE140 cells. Efficiency of RIPK3 knockdown was
confirmed by western blot analysis (Figure 4A). Knockdown of
RIPK3 (RIPK3-KD) markedly suppressed cisplatin-induced cell
death and considerably increased colony formation upon cisplatin
treatment compared with control vector cells (Figure 4B and C).
We also found that Bcl-2 and survivin were significantly
upregulated in the RIPK3-KD KYSE140 cells in response to
cisplatin compared to the parental cells (Figure 4D). Our data
show that RIPK3 is required for cisplatin-induced cell death in
KYSE140 cells.
It has been reported that necrostatin-1 (Nec-1), a RIPK1-
specific inhibitor, can block necroptosis [38]. We tested the effects
of Nec-1 on cisplatin-induced death in KYSE140 cells. Impor-
tantly, Nec-1 significantly inhibited the cisplatin-induced loss of
cell viability (Figure 4E). Notably, Nec-1 also significantly
protected clonogenic survival of KYSE140 cells after cisplatin
treatment (Figure 4F). We also used siRNA to knock down RIPK1
to test the requirement for necrosis in cisplatin-induced cell death.
Efficiency of siRNA-mediated knockdown of RIPK1 protein was
confirmed by western blot analysis (Figure 4G). RIPK1 knock-
down profoundly rescued cisplatin-induced cell death (Figure 4H),
indicating that RIPK1 is required for cisplatin-induced cell death.
These results indicate that both RIPK1 and RIPK3 are required
for cisplatin-triggered necrosis and for protection against long-
term clonogenic survival.
Gene expression changes in the cisplatin-treated
KYSE140 cells
To further investigate the mechanism of cisplatin-induced
necrosis in the KYSE140 cells, the Affymetrix Human Genome
U133 plus 2.0 arrays were used to analyze mRNA changes in
cisplatin-treated KYSE140 cells. The array data were analyzed
using the Significance Analysis of Microarrays (SAM 3.02)
software. The cutoff criteria for significantly differentially ex-
pressed genes were set as a ratio of .2-fold difference in
expression and an adjusted P value of ,0.05. In total, 531 genes
fulfilled the stringent cutoff criteria; 94 genes were upregulated,
whereas 437 genes were downregulated in the cispltin-treated
group. Within the upregulated genes, we grouped similar
annotation terms into clusters using DAVID functional annotation
clustering to measure the relationships between the annotation
terms and their co-association with the genes [30]. Notably, the
upregulated genes were predominantly involved in the regulation
of transcription, programmed cell death, response to changes in
oxygen levels, and response to cytokine stimulus (Figure 5A). The
complete list of upregulated and downregulated genes referenced
to the canonical biological pathways is available in Table S1 & S2.
To better understand how the KYSE140 cells are resistant to
apoptosis induction after cisplatin treatment, genes associated with
programmed cell death, including FOS, JUN, HSPA1A, TNFa,
RIPK3, MLKL, BIRC5, CYCS, APAF1, CASP9 and CASP3, were
selected for validation of the microarray results by real-time PCR
and western blot analyses. The mRNA levels of FOS, JUN,
HSPA1A and BIRC5, which are associated with apoptotic
resistance, were significantly elevated in the KYSE140 cells after
treatment with cisplatin for 6 h. Furthermore, the mRNA levels of
TNFa, RIPK3 and MLKL, which are associated with necrosis, were
greatly increased in the cisplatin-treated KYSE140 cells (Figure
5B). Additionally, the mRNA levels of APAF1, CASP9 and CASP3,
which are associated with apoptosis, were either unchanged or
partially decreased following cisplatin treatment. Therefore,
transcript analysis showed that cisplatin treatment facilitates
transcription of necrosis-associated genes but not apoptotic genes
in KYSE140 cells.
The expression levels of FOS, CASP9, RIPK3, MLKL, CYCS
and survivin were further evaluated using western blot analysis
(Figure 5C). The FOS protein level was markedly increased in the
KYSE140 cells after cisplatin treatments for 6, 12 and 24 h. The
RIPK3, CYCS and survivin expression levels were also higher in
the cisplatin-treated cells. Furthermore, we examined whether
cisplatin-induced cell death depended on differential gene
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expression in KYSE140 and EC0156 cells. Induction of RIPK3
and MLKL was observed in KYSE140 cells and reduced in
EC0156 cells, which undergo apoptosis after cisplatin treatment
[19]. In contrast, massive induction of CYCS, APAF1 and CASP9
occured in EC0156 but not in KYSE140 cells (Figure 5D).
Together, these data demonstrate that cisplatin triggers necrosis in
Figure 3. Cisplatin triggers the assembly of necrosome via autocrine production of TNFa in KYSE140 cells. (A) KYSE140 cells were
treated with 10 mM cisplatin for 6, 12, or 24 h, and the RIPK3 mRNA level was determined by RT-PCR. The relative density was compared to the
GAPDH control. (B) The RIPK3 protein expression was determined by western blot analysis. The levels of RIPK3 protein were quantified and
normalized to b-Actin. (C) Cisplatin promotes TNFa transcription. KYSE140 cells were treated with 10 mM cisplatin for the indicated time points, and
the TNFa mRNA levels were analyzed by RT-PCR. The relative density was compared to the GAPDH control. (D) Cisplatin promotes autocrine
production of TNFa. KYSE140 cells were treated with cisplatin for the indicated time points, and the level of TNFa secretion in the supernatant was
measured by ELISA. (E) RIPK3 interacts with RIPK1 and MLKL. After treatment with cisplatin for 12 and 24 h, RIPK1 and MLKL were
immunoprecipitated using anti-RIPK1 or anti-MLKL antibodies. RIPK1, RIPK3 and MLKL were detected by western blot analysis. (F) KYSE140 cells were
treated with 10 mM cisplatin for 6 or 12 h. Mitochondrial and cytosolic fractions were isolated from the treated cells and analyzed for the indicated
proteins with western blotting. AIF was used as a control for mitochondrial fraction and loading.
doi:10.1371/journal.pone.0100127.g003
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Figure 4. RIPK3 is required for cisplatin-induced necrosis. (A) Effects of RIPK3 knockdown were determined using western blot analysis, b-
Actin as a loading control. (B) RIPK3-KD-F2 clones and the parental cells were treated with 10 mM cisplatin for 24 h. Cell viability was assessed by MTT
assay. The data represent the mean percentage6 SD of cell death compared to parental cells. (C) The long-term viability of the cells was determined
after cisplatin treatment for 6 h in RIPK3-KD cells using the colony formation assay. (D) Western blot analysis of Bcl-2 and survivin in the parental and
RIPK3-KD-F2 cells after treatment with 10 mM cisplatin for 6, 12, or 24 h. b-Actin was used as a loading control. (E) KYSE140 cells were pre-incubated
for 1 h with 20 mM Nec-1 or DMSO and then treated with 10 mM cisplatin for 24 h. Cell viability was determined using an MTT assay and is expressed
as percentage of DMSO control. (F) KYSE140 and EC0156 cells were pre-incubated for 1 h with 20 mM Nec-1 or DMSO and then treated with 10 mM
cisplatin for 24 h before medium was replaced with fresh medium. Colonies were identified using crystal violet staining and counted under the
microscope. (G) Effects of RIPK1 knockdown were analyzed by western blotting, b-Actin as a loading control. (H) KYSE140 cells with RIPK1 siRNA were
treated with the indicated concentrations of cisplatin for 24 h. The data represent the mean percentage 6 SEM of cell death versus control cells.
doi:10.1371/journal.pone.0100127.g004
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Figure 5. Clustering display of the microarray data after cisplatin treatment. (A) RNA was extracted using an RNA isolation kit for
microarray analysis after cisplatin treatment for 6 h. The up-regulated genes were functionally classified based on their biological process using the
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KYSE140 cells by increasing the expression of necrosis-associated
genes as well as anti-apoptotic genes.
Cisplatin-induced necrosis is enhanced by RIPK3
overexpression in cells with apoptosis blocking
To further examine the role of RIPK3 in necrosis in ESCC
cells, a PCI-RIPK3 expression vector was used to express RIPK3
in KYSE410 cells which was an innate RIPK3-deficient. RIPK3
overexpression was confirmed by western blot analysis after PCI-
RIPK3 transfection and the isolation of stable drug-resistant clones
(Figure 6A). One of the stable clones, RIPK3-D8, was chosen for
analysis to test whether RIP3 overexpression sensitizes KYSE410
cells to cisplatin. As shown in Figure 6B, RIPK3 overexpression
significantly increased the cisplatin-induced cell death of
KYSE410 cells. To further investigate whether blocking apoptosis
enhances cisplatin-induced cell death, Z-LEHD and Z-DEVE,
specific inhibitors of caspase-9 and caspase-3, respectively, were
used to block apoptosis. Importantly, the addition of Z-LEHD and
Z-DEVE did not affect cell death after cisplatin treatment in
RIPK3-overexpressing KYSE410 cells, but it significantly reduced
cell death in parental cells (Figure 6C). These results suggest that
cisplatin induced cell death through programmed necrosis in
RIPK3-overexpressing cells after cisplatin treatment. Our obser-
vations demonstrated that RIPK3-mediated programmed necrosis
plays a partial role during conditions of DNA damage.
RIPK3 upregulation suppresses in vivo xenograft tumor
growth
To explore whether overexpression of RIPK3 in the KYSE410
cells affects tumor growth, we assessed the xenograft growth
between parental and RIPK3-D8 cells. The size of the RIPK3-
overexpressing tumors was significantly reduced compared to the
parental KYSE410 tumors (P,0.01; Figure 6D). H&E and RIPK3
staining showed a number of necrotic foci in tissue from RIPK3-
overexpressing xenograft tumors, and this reduced the tumor size
(Figure 6E). These results show that the mitigation in xenograft
tumor growth can be attributed to the RIPK3-mediated necrosis
in the KYSE410 cells overexpressing RIPK3.
The above data provide a rationale to better understand the
molecular mechanism of cisplatin-induced necrosis. We therefore
propose a summary model to explain how cisplatin induces
programmed necrosis in ESCC cells, illustrated in Figure 7: (i)
promotion of necrosome assembly via autocrine production of
TNFa, leading to necrosis, (ii) requirement of RIPK3 for cisplatin-
induced necrosis, and (iii) inhibition of endogenous apoptotic
pathways. These results showed that RIPK3-mediated pro-
grammed necrosis plays a critical role in the suppression of the
intrinsic apoptotic pathway and is essential for the efficacy of
cisplatin in esophageal cancer chemotherapy.
Discussion
Although apoptosis has been implicated in cisplatin-mediated
cytotoxicity, cisplatin has also been shown to induce non-apoptotic
cell death. In recent years, the molecular mechanisms underlying
necrosis have been increasingly realized as an important form
mechanism of programmed cell death. Necrosis in cancer cells
usually occurs when the apoptosis machinery is inhibited or absent
[39,40,41]. Our previous data indicated that efficient knockdown
of pro-apoptotic SMAC protein significantly attenuates the
response of esophageal cancer cells to cisplatin [27]. In the
present study, we found that cisplatin selectively induces necrosis
in KYSE140 cells, which are endogenously deficient in SMAC
expression. On basis of the following observations: (i) little nuclear
fragmentation and changes in mitochondrial membrane potential
were detected in KYSE140 cells in cisplatin-induced cell death; (ii)
the release of LDH, ROS production and caspase-independent
cell death were observed; and (iii) the visualization of disrupted
cytoplasimic membranes using TEM. Further, autocrine produc-
tion of TNFa, as the pro-death signal, was identified in cisplatin-
induced necrotic cell death. This result is consistent with reports
showing that autocrine production of TNFa enhanced cellular
necrosis in cisplatin-induced acute renal failure [42]. Secretion of
endogenous TNFa has been reported to induce downstream
signaling, triggering cell death in zVAD-induced necrotic cell
death [34]. Thus, our data suggest that cisplatin-induced
programmed necrosis in KYSE140 cells is initiated by the
autocrine production of TNFa.
Recent advances have elucidated the pathway leading to TNFa-
induced programmed necrosis and the core components of the
necrosis-inducing necrosome complexes, including RIPK1,
RIPK3 and MLKL [25,36,43]. Consistent with these results, our
data demonstrate that cisplatin-induced programmed necrosis in
KYSE140 cells is primarily executed by necrosome formation.
The RIPK3/RIPK1/MLKL necrosome complex was increased
upon the induction of necrosis, as indicated by immunoprecipi-
tation using anti-RIPK1 and anti-MLKL antibodies in KYSE140
cells. Recently, RIPK3-dependent necrosis has shown to be a
common cell-death pathway involved in a variety of pathological
conditions [43,44,45]. RIPK3 can mediate embryonic lethality in
caspase-8-deficient mice through an alternative RIPK3-dependent
necrotic cell death pathway [8]. However, it is currently unclear
whether RIPK3-mediated necrosis is associated with cisplatin-
induced cell death. Our results indicate that RIPK3 is required for
cisplatin-induced necrosis in the ESCC cells. This is because (i)
mRNA and protein levels of RIPK3 were upregulated after
cisplatin treatment; (ii) knockdown of RIPK3 by shRNA
prominently attenuated cisplatin-induced necrosis in the SMAC-
deficient KYSE140 cells; (iii) the necrotic complex including
RIPK1, RIPK3 and MLKL was formed, and the expression levels
of its components increased; (iv) overexpression of exogenous
RIPK3 still maintained the sensitivity of KYSE410 cells to
cisplatin in the presence of caspase inhibitors; (v) RIPK3
overexpression reduced xenograft tumor growth. Our study
provides several lines of evidence that RIPK3 plays a key role in
cisplatin-induced necrosis and provides new insight into the
mechanism of cisplatin-induced necrosis.
It is greatly appreciated that RIPK1 is crucial for necrosome
formation and for the execution of necrosis [46,47]. Recent
investigations demonstrated that the formation of the RIPK1-
RIPK3 complex is a crucial step in RIPK3 kinase activation,
which in turn regulates cellular energy metabolism and the
induction of programmed necrosis following stimulation with
TNFa or other agonists [17,24,25]. Consistent with these findings,
DAVID functional annotation clustering tool. (B) The mRNA levels of cell-death-associated genes in KYSE140 cells treated with 10 mM cisplatin for 6 h
were determined by real-time RT-PCR. The data represent the mean 6 SEM of relative mRNA levels versus untreated cells. (C) Protein levels of FOS,
RIPK3, MLKL, Cytochrome c, survivin and caspase-9 in KYSE140 cells after treatment with 10 mM cisplatin for the indicated time points were analyzed
by western blotting. (D) The mRNA levels of cell-death-associated genes in KYSE140 and EC0156 cells treated with 10 mM cisplatin for 6 h were
determined by real-time PCR. **, P,0.05; ***, P,0.01.
doi:10.1371/journal.pone.0100127.g005
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our results showed that RIPK1 is necessary for cisplatin-induced
necrosis, as both siRNA and pharmacological inhibition of RIPK1
attenuate cisplatin-induced cell death. Thus, using selective
knockdown of different individual components of the necrosome,
we provide evidence that cisplatin induces necrosis by enhancing
the recruiment of the necrosome to excute cell death in ESCC
cells. Identification of the mechanism by which RIPK3 regulates
cisplatin-induced programmed necrosis may help predict the
tumor’s response to chemotherapy and radiotherapy.
Although apoptosis is the predominant pathway of cisplatin-
induced cell death in cancer cells, necrosis as an alternative
pathway is increasingly appreciated for drug cytotoxicity when the
apoptotic machinery is suppressed [34,39,48]. The current study
shows that the apoptotic machinery was attenuated during
cisplatin-induced necrosis in KYSE140 cells. This is because (i)
the apoptotic response was decreased due to the downregulation of
caspase-9, SMAC deficiency, and the lack of caspase-3 activity;
and (ii) microarray analysis demonstrated an anti-apoptotic
molecular expression pattern involving increased expression of
Figure 6. RIPK3 overexpression inhibits tumor growth. (A) RIPK3 overexpression was analyzed with western blot analysis in the stable
KYSE410 clones. (B) RIPK3 overexpression clones and the parental cells were treated with 10 mM or 20 mM cisplatin for 24 h. Cell viability was assessed
by flow cytometry. The data represent the mean percentage6 SD of viable cells compared to parental cells. (C) KYSE410-vec and RIPK3-D8 clone cells
were treated with 10 mM cisplatin combined with a caspase inhibitor, z-LEHD (5 mM) or z-DEVD (5 mM), for 24 h. Cell viability was determined using
an MTT assay. (D) Tumor volume was measured every 2 to 3 days after treatment. RIPK3-D8 clone cells decreased the growth of the xenograft tumors
compared to the control group (P,0.001). (E) Reduced tumor growth in the RIPK3-overexpressing cells compared to the parental KYSE410 cells. The
parental and RIPK3-D8 cells were suspended in 0.1 ml of PBS and injected into nude mice to establish xenograft tumors. The bottom panels show
H&E staining and the RIPK3 expression determined by immunostaining for xenograft tissues. i, H&E staining for control xenograft tissues; ii, H&E
staining for RIPK3-D8 xenograft tissue; iii, immunostaining for control xenograft tissues (6100); iv, immunostaining for RIPK3 overexpression in the
xenograft tissues (6100). RIPK3 localized mainly in the cytoplasm of the esophageal cancer epithelial cells.
doi:10.1371/journal.pone.0100127.g006
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anti-apoptotic genes and reduced expression of pro-apoptotic
genes, leading to the suppression of the apoptotic pathway. It is
widely known that tumor cells can circumvent apoptosis by
increasing expression of anti-apoptotic regulators or by downreg-
ulating pro-apoptotic factors [6]. When apoptosis is completely
blocked by a caspase inhibitor, such as z-VAD-fmk, RIPK3 is
capable of driving necrosis in response to TNFa in some cell types
[17,24,33]. In our study, microarray data showed that three genes
(FOS, JUN, BIRC5) associated with the anti-apoptotic response
were elevated in the cisplatin-treated esophageal cancer cells. FOS
and JUN are the immediate early genes that are activated in signal
transduction systems after different types of stresses, and these
genes have been associated with cisplatin resistance through their
anti-apoptotic effects [49,50,51,52]. Our data showed that FOS
was dramatically upregulated in the cisplatin-treated group, as
shown by microarray analysis and confirmed by RT-PCR and
western blot analyses. We also identified autocrine production of
TNFa in supernatants after cisplatin treatment in KYSE140 cells.
Previous work has suggested that the TNFa promoter contains
AP-1 response elements [53]. Fos, in combination with Jun, forms
the AP-1 early response transcription factor in transcriptional
regulation. Therefore, it appears that the upregulation of FOS and
JUN may promote the transcription machinery for TNFa
expression and autocrine secretion to the medium in cisplatin-
induced necrosis in ESCC cells. Our data also showed the up-
regulation of proteins such as HSP70, BCL-2 and BIRC5 in the
cisplatin-treated esophageal cancer cells, indicating an increase in
the anti-apoptotic molecular pattern. Collectively, these data
clearly demonstrate that necrosis is an essential complementary
mechanism of cisplatin-induced cell death, especially when the
apoptotic pathway is blocked.
In summary, our study has several important implications. First,
we demonstrated a pathway by which cisplatin triggers pro-
grammed necrosis, promoting necrosome assembly via autocrine
production of TNFa and leading to necrosis, during inhibition of
endogenous apoptotic pathways. Notably, RIPK3 is required for
cisplatin-induced programmed necrosis in esophageal cancer cells.
Moreover, an anti-apoptotic molecular expression pattern that
blocks the apoptotic pathway in response to cisplatin was
confirmed by microarray analysis. Our data indicate that RIPK3,
necrosomes and autocrine production of TNFa contribute to
cisplatin sensitivity by initiating necrosis when the apoptotic
pathway is blocked in esophageal cancer cells. A better under-
standing of the events that activate the necrotic signaling pathway
induced by cisplatin is extremely important for improving cancer
chemotherapy by exploiting the necrotic machinery. Our results
suggest that activation of programmed necrosis is an alternative
strategy for killing apoptosis-resistant tumor cells. Sensitivity to
necrosis should be considered when defining the susceptibility of
individual esophageal cancers to cisplatin.
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